Novartis presents new data in breast, prostate cancer at ESMO

• Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali^®

• Data from VISION study reporting associations between magnitude of PSA decline from baseline and clinical outcomes with Pluvicto^® in patients with mCRPC

• Overall survival and safety findings for first-line tislelizumab in unresectable hepatocellular carcinoma from RATIONALE 301, the eighth positive clinical trial readout for tislelizumab 

Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.

“We are excited to share the data being presented across our portfolio of cancer therapies, which reinforce our commitment to pursuing every possible approach to address the urgent and significant unmet medical needs of people living with cancer,” said Jeff Legos, Executive Vice President, Global Head of Oncology & Hematology Development, Novartis. “Our presentations at ESMO will highlight our continued dedication to advancing innovative treatment options for these critical diseases.”

https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-presents-new-data-in-breast-and-prostate-cancer-at-ESMO-41645448/